Unknown

Dataset Information

0

Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease.

ABSTRACT:

Clinical trial registration

NCT03760146, NCT03828617.

SUBMITTER: Sabharwal C 

PROVIDER: S-EPMC9746485 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease.

Sabharwal Charu C   Sundaraiyer Vani V   Peng Yahong Y   Moyer Lisa L   Belanger Todd J TJ   Gessner Bradford D BD   Jodar Luis L   Jansen Kathrin U KU   Gruber William C WC   Scott Daniel A DA   Watson Wendy W  

Human vaccines & immunotherapeutics 20221111 6

<h4>Clinical trial registration</h4>NCT03760146, NCT03828617. ...[more]

Similar Datasets

Unknown Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age.
| S-EPMC8492133 | biostudies-literature
Unknown Immunogenicity and safety of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults ≥18 years of age in India: A phase 3 single-arm trial.
| S-EPMC12785191 | biostudies-literature
Unknown Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years.
| S-EPMC9427137 | biostudies-literature
Unknown Immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine as a booster dose in 12- to 18-month-old children primed with 3 doses of 7-valent pneumococcal conjugate vaccine.
| S-EPMC4186054 | biostudies-literature
Unknown 1240. Persistence of Circulating Antibody Through 12 Months Following Vaccination With a 20-Valent Pneumococcal Conjugate Vaccine in Adults 60–64 Years of Age
| S-EPMC7776953 | biostudies-literature
Unknown Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States.
| S-EPMC8443440 | biostudies-literature
Unknown Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine Versus a 13-Valent Vaccine in Infants: A Systematic Review and Meta-Analysis.
| S-EPMC12656742 | biostudies-literature
Unknown A Phase 3, Single-arm Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine in Healthy Children 15 Months Through &lt;18 Years of Age.
| S-EPMC11090515 | biostudies-literature
Unknown Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults ≥65 years old.
| S-EPMC10165018 | biostudies-literature
Unknown Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece.
| S-EPMC10570410 | biostudies-literature